新斯的明甲硫酸鹽注射液市場：按劑量、適應症、分銷管道、最終用途和地區分類

據估計，2026年新斯的明甲磺酸鹽注射液市值為1.796億美元，預計2033年將達到2.476億美元。預計從2026年到2033年，其複合年成長率將達到4.7%。

新斯的明甲磺酸鹽注射是一種膽鹼酯酶抑制劑，可用作重症肌無力的輔助治療藥物，也可在手術室和加護病房（ICU）中作為非去極化神經肌肉阻斷劑中毒的解毒劑。此藥主要透過抑制乙醯膽鹼酯酶發揮作用，乙醯膽鹼酯酶負責分解神經肌肉接頭處的神經傳導物質乙醯膽鹼。透過抑制此酶，新斯的明甲磺酸鹽可延長乙醯膽鹼的作用時間，進而增強神經肌肉傳導和肌肉力量。此藥有助於控制重症肌無力的症狀，例如四肢、身體軀幹、喉嚨和眼部骨骼肌無力。過量用藥或在高度敏感的患者中，可能會增加神經肌肉接頭處的刺激，從而引起噁心、唾液分泌增加和肌肉痙攣等副作用。

市場動態：

人口老化加劇將持續推動全球新斯的明甲磺酸鹽注射液市場在預測期間的成長。老年人更容易罹患重症肌無力等神經系統疾病，而新斯的明甲磺酸鹽注射是治療這些疾病的常用藥物。醫療保健成本的不斷上漲也將持續促進全球新斯的明甲磺酸鹽注射液市場在預測期內的成長。獸醫領域的成長也將為全球新斯的明甲磺酸鹽注射液市場在預測期內創造新的機會。新斯的明甲磺酸鹽注射液也應用於獸醫領域，尤其用於治療動物的多種神經肌肉疾病。這有望開闢新的商業性前景，從而提高新斯的明甲磺酸鹽注射液在獸醫領域的應用和普及程度。

預計在預測期內，知識和診斷的缺乏將阻礙全球新斯的明磺酸鹽注射劑市場的成長。

本研究的主要特點：

• 本研究確定了各個細分市場的潛在收入成長機會，並為該市場說明了一個有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數創建了全球新斯的明甲磺酸鹽注射液市場主要公司的概況：公司概況、產品系列、主要亮點、財務表現和策略。
• 本研究涵蓋的主要公司包括：百特國際、輝瑞、費森尤斯卡比、勃林格殷格翰、邁蘭、諾華國際、梯瓦製藥工業、希克瑪製藥、GlaxoSmithKline Plc、太陽製藥工業、山德士（諾華旗下業務部門）、雅科德醫療保健、蘭尼特公司、馬林克羅德製藥和魯賓有限公司。
• 本報告提供的見解將有助於各公司的行銷負責人和經營團隊就未來的產品發布、產品改進、市場擴張和行銷策略做出明智的決策。
• 本報告旨在為全球新斯的明甲磺酸鹽注射液市場的各個相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過利用分析全球新斯的明甲磺酸鹽注射液市場中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
    • 需要使用新斯的明治療的疾病（如重症肌無力和術後腸阻塞）的盛行率增加。
  • 抑制因子
    • 缺乏知識和診斷
  • 機會
    • 獸醫學的發展
• 影響分析
• 主要亮點
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特五力分析
• 併購情景

第4章：全球新斯的明甲磺酸鹽注射液市場

• 供給面和需求面分析
• 經濟影響

第5章 全球新斯的明甲硫酸鹽注射液市場：依劑量分類，2021-2033年

• 1 mg/mL
• 0.5 mg/mL

第6章 全球新斯的明甲硫酸鹽注射液市場：依適應症分類，2021-2033年

• 重症肌無力
• 解除神經肌肉阻斷

第7章 全球新斯的明甲硫酸鹽注射液市場：依通路分類，2021-2033年

• 醫院藥房
• 零售藥房
• 網路藥房

第8章 全球新斯的明甲硫酸鹽注射液市場：依最終用戶分類，2021-2033年

• 醫院
• 專科診所
• 門診手術中心

第9章 全球新斯的明甲硫酸鹽注射液市場：依地區分類，2021-2033年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 法國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • ASEAN
  • 澳洲
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 中東和非洲
  • GCC
  • 以色列
  • 其他中東國家
  • 北非
  • 中非
  • 南非

第10章 競爭格局

• Baxter International Inc.
• Pfizer Inc.
• Fresenius Kabi AG
• Boehringer Ingelheim GmbH
• Mylan NV
• Novartis International AG
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Ltd.
• Sandoz（a division of Novartis）
• Accord Healthcare Inc.
• Lannett Company, Inc.
• Mallinckrodt Pharmaceuticals
• Lupin Limited

第11章

• 調查方法
• 關於本公司

Neostigmine Methylsulfate Injection Market is estimated to be valued at USD 179.6 Mn in 2026 and is expected to reach USD 247.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 4.7% from 2026 to 2033.

Neostigmine methylsulfate injection is a cholinesterase inhibitor that is used as an adjunct in the treatment of myasthenia gravis and as an antidote in the treatment of non-depolarizing neuromuscular blocking agent toxicity in the operating room or intensive care unit setting. It acts by inhibiting the acetylcholinesterase enzyme, which normally breaks down the neurotransmitter acetylcholine at the neuromuscular junction. By inhibiting this enzyme, neostigmine methylsulfate prolongs the actions of acetylcholine, increasing neuromuscular transmission and muscle strength. It helps in the management of myasthenia gravis symptoms such as weakness of the skeletal muscles of the extremities, trunk, throat, and eyes. In overdose or sensitive patients, it can cause increased stimulation at the neuromuscular junction and produce side effects such as nausea, increased saliva, and muscle cramps.

Market Dynamics:

The increasing geriatric population will continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The elderly are more susceptible to neurological conditions like myasthenia gravis, which frequently needs to be treated with injections of neostigmine methylsulfate. Rising medical expenditures will also continue to fuel the growth of the global neostigmine methylsulfate injection market over the forecast period. The growth of veterinary medicine will create new opportunities for the global neostigmine methylsulfate injection market over the forecast period. Injections of neostigmine methylsulfate are also employed in veterinary medicine, particularly for the treatment of a few neuromuscular diseases in animals. It may open up new commercial prospects to increase the use and availability of neostigmine methylsulfate injections in the veterinary industry.

Lack of knowledge and diagnosis is expected to hamper the growth of the global neostigmine methylsulfate injection market over the forecast period.

Key Features of the Study:

• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global neostigmine methylsulfate injection market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• The key companies covered as a part of this study include Baxter International Inc., Pfizer Inc., Fresenius Kabi AG, Boehringer Ingelheim GmbH, Mylan N.V., Novartis International AG, Teva Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Sandoz (a division of Novartis), Accord Healthcare Inc., Lannett Company, Inc., Mallinckrodt Pharmaceuticals, and Lupin Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global neostigmine methylsulfate injection market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neostigmine methylsulfate injection market

Detailed Segmentation:

• Global Neostigmine Methylsulfate Injection Market, By Dosage:
• 1 mg/mL
• 0.5 mg/mL
• Global Neostigmine Methylsulfate Injection Market, By Indications:
• Myasthenia Gravis
• Reversal of Neuromuscular Blockade
• Global Neostigmine Methylsulfate Injection Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Neostigmine Methylsulfate Injection Market, By End User:
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Regional Insights (Revenue, USD Mn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profile:
• Baxter International Inc.
• Pfizer Inc.
• Fresenius Kabi AG
• Boehringer Ingelheim GmbH
• Mylan N.V.
• Novartis International AG
• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• GlaxoSmithKline plc
• Sun Pharmaceutical Industries Ltd.
• Sandoz (a division of Novartis)
• Accord Healthcare Inc.
• Lannett Company, Inc.
• Mallinckrodt Pharmaceuticals
• Lupin Limited

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Neostigmine Methylsulfate Injection Market, By Dosage
  • Neostigmine Methylsulfate Injection Market, By Indication
  • Neostigmine Methylsulfate Injection Market, By Distribution Channel
  • Neostigmine Methylsulfate Injection Market, By End User
  • Neostigmine Methylsulfate Injection Market, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
    • Rising prevalence of diseases like myasthenia gravis and postoperative ileus requiring neostigmine
  • Restraints
    • Lack of knowledge and diagnosis
  • Opportunities
    • Growth of veterinary medicine
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER€(TM)s Analysis
• Merger and Acquisition Scenario

4. Global Neostigmine Methylsulfate Injection Market

• Supply Side and Demand Side Analysis
• Economic Impact

5. Global Neostigmine Methylsulfate Injection Market, By Dosage, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• 1 mg/mL
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• 0.5 mg/mL
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

6. Global Neostigmine Methylsulfate Injection Market, By Indication, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Myasthenia Gravis
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Reversal of Neuromuscular Blockade
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

7. Global Neostigmine Methylsulfate Injection Market, By Distribution Channel, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

8. Global Neostigmine Methylsulfate Injection Market, By End User, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Hospitals
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Specialty Clinics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Ambulatory Surgical Centers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

9. Global Neostigmine Methylsulfate Injection Market, By Region, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Region 2022 - 2033
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East & Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Dosage, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
    • North Africa
    • Central Africa
    • South Africa

10. Competitive Landscape

• Baxter International Inc.
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Fresenius Kabi AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim GmbH
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Mylan N.V.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Novartis International AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hikma Pharmaceuticals PLC
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Sandoz (a division of Novartis)
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Accord Healthcare Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Lannett Company, Inc.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Mallinckrodt Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Lupin Limited
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

11. Section

• Research Methodology
• About us